Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-masked randomized cross-over comparison of Xalacom and Combigan in primary open angle glaucoma or ocular hypertension
2005-004060-24Phase 3Completed
- Sponsor
- Department of Clinical Pharmacology
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of timolol and brimonidine tartrate + timolol maleate in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Department of Clinical Pharmacology. Primary endpoints: Treatment completion at 12 weeks, Change in intraocular pressure and 1 more. Started Oct 2005; status: completed.
02
Drugs
timololbrimonidine tartrate + timolol maleate
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2005-004060-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004060-24.